Summary. The ability to identify non-responders to cytotoxic chemotherapy has signi®cant clinical and economic bene®ts. Differential staining cytotoxicity (DiSC) assays were performed in 34 previously treated patients with chronic lymphocytic leukaemia prior to treatment with cladribine. Of the 28 identi®ed as ex vivo sensitive, 26 achieved a complete (CR) or partial response (PR) (median length of response 1´5 years, median survival 3´37 years) and two had a >70% fall in lymphocytes: six identi®ed as ex vivo resistant failed to respond. The DiSC assay can accurately identify a subgroup of patients resistant to cladribine.
The purine analogue cladribine (2-chloro-deoxyadenosine) can achieve high levels of overall responses and substantial numbers of complete responses in chronic lymphocytic leukaemia (CLL). However, the ability to identify nonresponders to treatment would have signi®cant clinical and economic bene®ts. A well-validated ex vivo method, the differential staining cytotoxicity (DiSC) assay, has been previously evaluated as a tool for identifying response to treatment with purine analogues (Bosanquet, 1991; Bosanquet & Bell, 1996; Bosanquet et al, 1999) .
This study aimed to investigate the prognostic value of the DiSC assay in 34 patients with CLL of B-cell origin who were either unresponsive to, or had relapsed following, one or more treatments including chlorambucil, anthracycline/ anthracenedione or¯udarabine.
MATERIALS AND METHODS
Patients. 34 CLL patients entered the study: 23 men and 11 women (mean age 67, range 45±83). They were either unresponsive to standard therapy or required a change of therapy because of shortened remission duration or advanced disease. Patients were excluded if they had a life expectancy of <6 months.
DiSC assay. DiSC assays were performed before cladribine treatment using published methods (Bosanquet & Bell, 1996) . Mononuclear cells were isolated from blood samples and incubated with cladribine at 1´024, 0´256, 0´064, 0´016 and 0´004 mg/ml and the LC 90 determined (minimum concentration of cladribine required to kill 90% of lymphocytes). The results were not made known to the clinicians managing the patients.
Cladribine treatment. Cladribine (Leustat, Janssen-Cilag Ltd) was administered as an intravenous (i.v.) 2 h infusion at a dose of 0´12 mg/kg each day for 5 consecutive days. Treatment was repeated at 28 d intervals. Depending on the onset and degree of response, patients received between four and six cycles. Those who showed no response to one cycle received no further treatment. Patients received full supportive care. Cycles could be postponed in the event of infection or thrombocytopenia (de®ned as a drop in platelets of >50% of pre-treatment values or <60´10 9 /l on the day before the next cycle). Responses were assessed using the National Cancer Institute (NCI) criteria to determine study outcomes (Cheson et al, 1996) . Following cessation of treatment, patients were monitored for duration of response (calculated from 4 weeks after last cladribine treatment) and survival (calculated from treatment start). 
RESULTS

DiSC assay
Data were available from all 34 patients. Patients could be separated into two distinct groups: 6/34 patients were ex vivo resistant (LC 90 >1 mg/ml) and 28/34 patients were ex vivo sensitive (LC 90 < 0´3 mg/ml). Assay results correlated with clinical response (Fig 1) : 26 of the`sensitive' group achieved a complete response (CR) or partial response (PR), and two had >70% reduction in lymphocytes but withdrew after one cycle because of adverse events (fatal myocardial infarction and haemolytic anaemia). All six patients in the resistant group failed to respond: two showed a minor and short-lived reduction in their lymphocyte count. The proportion of patients for whom the DiSC assay correctly identi®ed clinical outcome was therefore 32/34 (94%; 95% CI 86±100%).
Response and survival 7/34 patients (21%; CI 7±34%) achieved a CR, 19/34 (56%; CI 39±73%) achieved a PR. Two patients showed a 71% and 88% reduction in lymphocytes but did not meet the full response criteria before withdrawing from the study. The remainder (6/34, 18%; CI 5±30%) had no response. Response rates strati®ed by Binet stage and W.H.O. performance status at baseline are shown in Table I .
Median remission duration of the responders was 1´50 years (range 0±3´23) for the PR patients and 2´30 years (range 0´71±3´74) for the CR patients. Three of the CR patients and one of the PR patients remain in remission >3 years after treatment; one PR patient died of pneumonia while still in PR.
Survival of DiSC-assay-sensitive versus DiSC-assay-resistant patients is presented in Fig 2. DiSC-assay-sensitive patients survived a median of 3´37 years (CI 2´2±4´6 years). 11 patients were still alive at analysis at 3´6±4´8 years (mean 4´2 years). Three of the assay-resistant patients died very soon after cladribine treatment commenced, a similar trend to that seen following¯udarabine treatment of ex vivō udarabine-resistant patients (Bosanquet et al, 1999) . Of the other three patients, one responded to splenectomy and two survived with supportive care but poor quality of life for >3 years. Due to the long survival of these three patients, no signi®cant difference in survival was seen between the DiSCassay-sensitive and DiSC-assay-resistant patients (P 0´12).
Previous treatment
Fourteen patients had received¯udarabine; 12 responded but later relapsed. The two other patients who had not responded to previous¯udarabine treatment were resistant to cladribine by DiSC assay and withdrew from the study because of persistent thrombocytopenia after one or two cycles of cladribine. Another patient developed autoimmune haemolytic anaemia during cladribine treatment and therefore withdrew, having previously stopped¯udarabine treatment for the same condition.
Adverse events
Five patients developed severe haemolysis shortly after treatment; 4/5 had positive direct antiglobulin tests (DAGT), two subsequently died, all four had previously received chlorambucil and¯udarabine. Haemolysis occurred during the ®rst (one), second (three) or third (one) cycle of cladribine, from 5±24 (median 18) days after cladribine administration. All four patients who received more than one cycle of cladribine achieved a partial response. These cases have been reported by Chasty et al (1998) . Six patients experienced persistent thrombocytopenia. Two other patients died during the course of treatment (from a myocardial infarct and cerebrovascular accident). Three patients developed further malignancies or disease progression.
DISCUSSION
In this study the DiSC assay identi®ed resistance to cladribine, having previously been shown to detect ex vivo sensitivity and resistance accurately in both solid and haematological tumours (Bosanquet, 1991; Bosanquet & Bell, 1996; Bosanquet et al, 1999) . Other groups have published preliminary results using ex vivo drug sensitivity tests in CLL with mixed success (Bromidge et al, 1998; Liu et al, 1997; Lambert et al, 1992; Hansen et al, 1991) . However, the results of this work and the powerful prognostic factor of the¯udarabine DiSC assay sensitivity for response and survival after¯udarabine (Bosanquet et al, 1999) suggest that the DiSC assay should be used routinely before purine analogues are administered to patients. Knowledge of ex vivo resistance enables patients who are unlikely to respond to avoid ineffective and potentially debilitating treatment. Patients with good performance status and in an early stage of their disease (i.e. W.H.O. grade 1 or Binet stage A) are more likely to achieve a CR or PR with cladribine (Table I) .
The overall response rate observed in this study (76%) is similar to that reported for untreated patients (73±87´5%) (Mulligan et al, 1996; Saven et al, 1995; Delannoy et al, 1995; Juliusson et al, 1996) . This group is therefore more sensitive than most previously treated patients ± indeed many patients had responded to their previous treatments. The median response duration compares favourably with previous reports.
In conclusion, the DiSC assay can delineate CLL patients who could, or who will not, bene®t from cladribine treatment.
